Goldman Sachs’s CureVac CVAC Stock Holding History

Goldman Sachs’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-19,200	Closed	-$1.05M	–	6488
2021 Q3	$1.05M	Buy	+19,200	New	+$1.16M	﹤0.01%	4703

Other funds holding CVAC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Goldman Sachs's CVAC Position: Q4 2025 in Review

Goldman Sachs sold out of CureVac (CVAC) in Q4 2025, closing a stake of 399,893 shares — an estimated $2.16M sold.

Goldman Sachs first reported a position in CVAC in Q3 2020 and held it in 21 quarters. The position peaked at $11.8M in Q4 2021. 57 funds tracked by Wall St. Rank hold CVAC as of Q4 2025.

Goldman Sachs reported no remaining CureVac position as of Q4 2025 after selling out during the quarter.
Goldman Sachs sold 399,893 CureVac shares in Q4 2025, an estimated $2.16M.
Goldman Sachs first reported a position in CureVac in Q3 2020 and held it in 21 quarters.
Goldman Sachs's CureVac position peaked at $11.8M in Q4 2021.
57 funds tracked by Wall St. Rank held CureVac as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.